Compare Avantis US Small Cap Value ETF (AVUV) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Moderna, Inc. — how do they compare? Avantis US Small Cap Value ETF trades at $124.85, while Moderna, Inc. trades at $66.76 (market cap $26.76B). The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| AVUV | MRNA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $124.94 | $81.80 |
52-Week Low | $90.37 | $22.36 |
Market Cap | — | $26.76B |
Enterprise Value | — | $22.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $123.97, up 0.02% on the day, with a bullish technical outlook supported by moving averages. The ETF focuses on U.S. small-cap value stocks, which have outperformed growth peers in 2026, driven by shifting rate expectations. Recent news highlights its role in diversifying tech-heavy portfolios and capturing the small-cap value premium.
Outlook remains positive as small-cap value gains favor amid economic shifts, though risks include higher volatility and sensitivity to interest rates. The fund offers growth potential but requires tolerance for the inherent risks of smaller companies.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
